NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free GDRX Stock Alerts $6.97 +0.31 (+4.65%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$6.52▼$7.0350-Day Range$6.38▼$8.3552-Week Range$4.14▼$9.37Volume1.12 million shsAverage Volume1.53 million shsMarket Capitalization$2.75 billionP/E RatioN/ADividend YieldN/APrice Target$8.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingHold2.47 Rating ScoreUpside/Downside26.5% Upside$8.78 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth34.78%From $0.23 to $0.31 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.67 out of 5 starsMedical Sector264th out of 910 stocksData Processing & Preparation Industry20th out of 60 stocks 4.2 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 10 buy ratings, 8 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GDRX. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 3.1 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GoodRx this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat Follows8 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.37% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 34.78% in the coming year, from $0.23 to $0.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -346.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -346.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 3.67. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesApril 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.April 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (GDRX)The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolioApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 23, 2024 | businesswire.comGDRX Alert: Rosen, Skilled Investor Counsel, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GDRXApril 22, 2024 | businesswire.comGDRX INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc. And Encourages Investors With Losses To Contact The FirmApril 16, 2024 | americanbankingnews.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Rating of "Hold" from AnalystsApril 13, 2024 | nasdaq.comMixed Inflation Readings Highlight Rocky WeekApril 11, 2024 | businesswire.comGoodRx Announces Date for First Quarter 2024 Earnings Release and Conference CallApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 10, 2024 | msn.comR1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech spaceApril 10, 2024 | markets.businessinsider.comGoodRx Holdings Analyst Turns Bullish Ahead Of Q1 EarningsApril 4, 2024 | msn.com‘Time to Hit Buy,’ Says Wells Fargo About These 2 StocksApril 2, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)April 2, 2024 | businesswire.comGoodRx Adds Publix to GoodRx Gold NetworkMarch 29, 2024 | finance.yahoo.comThis GoodRx Holdings Insider Increased Their Holding In The Last YearMarch 25, 2024 | msn.comWells Fargo upgrades GoodRx, stock jumps 10%March 25, 2024 | markets.businessinsider.comTelemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst SaysMarch 25, 2024 | fool.comWhy GoodRx Surged TodayMarch 20, 2024 | seekingalpha.comGoodRx Holdings: Large TAM Continues To Support GrowthMarch 16, 2024 | finance.yahoo.comRSI Apr 2024 10.000 putMarch 15, 2024 | finance.yahoo.comWall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should KnowMarch 14, 2024 | finance.yahoo.comGoodRx Interim CEO Extends Commitment to CompanyMarch 2, 2024 | seekingalpha.comGoodRx Holdings, Inc. (GDRX) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comGoodRx Holdings Full Year 2023 Earnings: EPS Misses ExpectationsMarch 2, 2024 | msn.comJP Morgan Upgrades GoodRx Holdings (GDRX)March 1, 2024 | finance.yahoo.comGoodRx upgraded, Fisker downgraded: Wall Street's top analyst callsMarch 1, 2024 | msn.comThese Analysts Increase Their Forecasts On GoodRx Following Q4 EarningsSee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/23/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryN/A Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees694Year FoundedN/APrice Target and Rating Average Stock Price Target$8.78 High Stock Price Target$14.00 Low Stock Price Target$4.50 Potential Upside/Downside+25.9%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio30.30 P/E Growth3.67Net Income$-8,870,000.00 Net Margins-1.18% Pretax Margin-7.41% Return on Equity2.45% Return on Assets1.25% Debt Debt-to-Equity Ratio0.85 Current Ratio7.12 Quick Ratio7.12 Sales & Book Value Annual Sales$750.27 million Price / Sales3.67 Cash Flow$0.43 per share Price / Cash Flow16.21 Book Value$1.93 per share Price / Book3.61Miscellaneous Outstanding Shares395,000,000Free Float389,586,000Market Cap$2.75 billion OptionableOptionable Beta1.42 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 45)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Key CompetitorsJanux TherapeuticsNASDAQ:JANXNeogenNASDAQ:NEOGPROCEPT BioRoboticsNASDAQ:PRCTIntegra LifeSciencesNASDAQ:IARTImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsGerber LLCBought 20,000 shares on 4/23/2024Ownership: 0.008%Counterpoint Mutual Funds LLCBought 15,052 shares on 4/15/2024Ownership: 0.009%Gerber LLCBought 11,200 shares on 3/5/2024Ownership: 0.003%Syon Capital LLCBought 25,000 shares on 2/26/2024Ownership: 0.006%Rip Road Capital Partners LPBought 361,294 shares on 2/14/2024Ownership: 0.434%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions Should I buy or sell GoodRx stock right now? 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares. View GDRX analyst ratings or view top-rated stocks. What is GoodRx's stock price target for 2024? 19 analysts have issued 12-month price targets for GoodRx's stock. Their GDRX share price targets range from $4.50 to $14.00. On average, they anticipate the company's share price to reach $8.78 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price. View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts. How have GDRX shares performed in 2024? GoodRx's stock was trading at $6.70 at the beginning of 2024. Since then, GDRX stock has increased by 3.6% and is now trading at $6.94. View the best growth stocks for 2024 here. When is GoodRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GDRX earnings forecast. How can I listen to GoodRx's earnings call? GoodRx will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) released its quarterly earnings data on Thursday, February, 29th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The business had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a positive trailing twelve-month return on equity of 2.45% and a negative net margin of 1.18%. What ETFs hold GoodRx's stock? ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include WisdomTree Growth Leaders Fund (PLAT), Global X Telemedicine & Digital Health ETF (EDOC) and Fidelity Digital Health ETF (FDHT).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has GoodRx issued on next quarter's earnings? GoodRx updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $800.0 million-$800.0 million, compared to the consensus revenue estimate of $790.5 million. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX). When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.01%) and Gerber LLC (0.01%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
